Orlinger
VICE PRESIDENT RESEARCH
HOOKIPA BIOTECH.
Austria
Biography
As Vice President Research at Hookipa, Dr. Klaus Orlinger is responsible for generation and characterization of prophylactic and therapeutic vaccines / immunotherapy candidates. He developed the HB-101 vaccine candidate of Hookipa’s cytomegalovirus vaccine. Klaus brings more than 10 years of experience in the field of virology, including involvement in the development and life cycle management of various vaccines and candidates for infectious diseases. Prior to joining Hookipa, he was leading a research team at Baxter Bioscience Molecular vaccines department. Klaus holds an MSc and PhD in genetics / microbiology from University of Vienna and Medical University Vienna, respectively.
Research Interest
PHARMA
